1. Home
  2. XAIR vs ADXN Comparison

XAIR vs ADXN Comparison

Compare XAIR & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$1.15

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

HOLD

Current Price

$7.90

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
ADXN
Founded
2011
2002
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
10.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
ADXN
Price
$1.15
$7.90
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
22.5M
8.7K
Earning Date
02-13-2026
12-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,802,000.00
$198,824.00
Revenue This Year
$127.85
$86.57
Revenue Next Year
$179.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
N/A
52 Week Low
$0.67
$6.51
52 Week High
$10.40
$12.05

Technical Indicators

Market Signals
Indicator
XAIR
ADXN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
XAIR
ADXN

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Share on Social Networks: